Company profile: Cellics Therapeutics
1.1 - Company Overview
Company description
- Provider of biomimetic nanomedicines based on cellular nanosponges—nanoparticles coated with cell membranes—to bind and neutralize bacterial toxins, cytokines, and viruses. Products include CTI-005, a red blood cell nanosponge for MRSA pneumonia, and CTI-111, a macrophage nanosponge for sepsis that absorbs and neutralizes toxins and inflammatory cytokines.
Products and services
- Cellular Nanosponges: Biomimetic nanoparticles coated with cell membranes that bind and neutralize bacterial toxins, inflammatory cytokines, and viruses in circulation, engineered to sequester diverse threats
- CTI-005: Nanoparticle-scale Red Blood Cell Nanosponge that absorbs and neutralizes MRSA bacterial toxins, engineered to treat MRSA pneumonia by toxin sequestration
- CTI-111: Cell-membrane-coated Macrophage Nanosponge that absorbs and neutralizes inflammatory cytokines to control inflammation, architected to treat sepsis by cytokine sequestration
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cellics Therapeutics
Alliqua
HQ: United States
Website
- Description: Provider of biomedical products and therapies, including custom electron-beam cross-linked hydrogels for medical and cosmetic applications and the UltraMIST ultrasound wound-healing therapy; develops, manufactures, and markets proprietary products leveraging a technology portfolio.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alliqua company profile →
Bioject
HQ: United States
Website
- Description: Provider of needle-free injection therapies to improve administration of liquid medications, including pharmaceuticals, vaccines, and biologics, using technology that forces medication at high speed through a tiny orifice held against the skin, with over 25 years of experience.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bioject company profile →
Softhale
HQ: Belgium
Website
- Description: Provider of soft mist inhalation (SMI) devices, including an innovative handheld non-thermal mechanical nebulizer, enabling effective respiratory delivery of pharmaceutical drugs to the lungs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Softhale company profile →
Qnovia
HQ: United States
Website
- Description: Provider of medtech and pharmaceutical drug-delivery solutions, including RespiRx, an inhalable prescription nicotine replacement therapy for smoking cessation; an inhaled drug delivery platform that optimizes and tracks dosing to improve efficacy and compliance; and a portable, orientation-agnostic vibrating mesh nebulizer with a digital metered dose interface, Bluetooth-enabled app, and a zero-maintenance disposable cartridge.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Qnovia company profile →
Suono Bio
HQ: United States
Website
- Description: Provider of ultrasound-mediated drug delivery platforms enabling ultra-rapid delivery of small molecules, biologics, and nucleic acids to the gastrointestinal tract and directly into cells without encapsulation; offerings include Ultrasonic Enhanced Delivery and SuonoCalm for treating inflammatory conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Suono Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cellics Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cellics Therapeutics
2.2 - Growth funds investing in similar companies to Cellics Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cellics Therapeutics
4.2 - Public trading comparable groups for Cellics Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →